Search
100,000 Patient data sets: The value of data sharing to accelerate blood cancer research.
With almost 100,000 patient data sets identified and 63,000 already transferred to the HARMONY Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into blood cancers.
Read more2013 & before
2013
EHA-SWG Scientific Meeting on Thrombocytopenia and Disorders of Platelet Function
September 27-29, 2013 | Lisbon, Portugal
EHA-ROHS-RSH Tutorial on Bone Marrow Transplantation
July 5-7, 2013 | Saint Petersburg, Russia
EHA Tutorial on Lymphoma
May 24-26, 2013 | Cape Town, South Africa
EHA-TSH Tutorial on Chronic Myeloproliferative…
EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
Read moreEHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding
Meeting chairs, Carlo Balduini and Anna Falanga
The meeting was well attended by more than 100 participants coming from over 20 different countries
Delegate: Great meeting.
EHA-NSHBT Sickle Cell Disease Webinar
EHA and the Topics-in-Focus Taskforce on Hemoglobinopathies are working with the Nigerian Society of Haematology and Blood Transfusion (NSHBT) to organize a webinar on Sickle Cell Disease (SCD).
Read moreSPC Advisory Board, EHA2025 Congress
Current committee members
Lorena Arranz, Norway
Peter Borchmann, Germany
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Matteo Della Porta, Italy
Michael Doubek, Czechia
Andreas Glenthøj, Denmark
Maria Gomes da Silva, Portugal
Julia Hauer, Germany
Daniel Hodson, United Kingdom
Cristina João, Portugal
Sören Lehmann, Sweden
Tamás Masszi, Hungary
Karinna Meijer, The Netherlands
Jamie O'Sullivan, Ireland
Cristina Papayannidis, Italy
France…
Gdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.